Natrium Chloratum Teva-„pm” (Sodium Chloride)

Sodium chloride provides isotonic Na+ and Cl‑ ions that expand the extracellular fluid compartment when administered intravenously. This increases plasma osmolarity, normalizes serum sodium levels, and supports cellular hydration, thereby re‑establishing fluid and electrolyte balance.

The dose of Natrium Chloratum Teva-„pm” is determined by the prescribing clinician based on the patient’s fluid status, electrolyte levels, and clinical condition. Dosage may be adjusted for age, weight, renal function, and the specific therapeutic goal.

Safety data for Natrium Chloratum Teva-„pm” in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Natrium Chloratum Teva-„pm”, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Natrium Chloratum Teva-„pm” is comparable to other 0.9% sodium chloride injection solutions in terms of isotonicity and electrolyte content. Differences may lie in manufacturing origin, regulatory compliance, and packaging. Clinicians choose based on supplier reliability, cost, and specific institutional requirements.

Store Natrium Chloratum Teva-„pm” at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect from moisture and direct sunlight, and avoid freezing. Follow standard aseptic handling procedures when preparing for intravenous administration.

The product is administered intravenously, either as a slow infusion or a controlled IV push, according to the prescriber’s instructions. Infusion rates should be adjusted based on the patient’s fluid status and clinical response.

Serious risks include severe hypernatremia, fluid overload leading to pulmonary edema or heart failure, and rare anaphylactic reactions. Monitoring of serum electrolytes and fluid balance is essential to mitigate these risks.

Patients with existing severe hypernatremia, uncontrolled fluid overload, or conditions that predispose to pulmonary edema should avoid this product unless a clinician determines that benefits outweigh risks. Caution is also advised in severe renal or cardiac impairment.